Medpace Holdings, Inc. (NASDAQ:MEDP) Receives $376.30 Average Price Target from Brokerages

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) have earned a consensus rating of "Hold" from the thirteen analysts that are presently covering the stock, Marketbeat reports. Eight investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $376.30.

Several research analysts have weighed in on the stock. Leerink Partnrs raised shares of Medpace to a "hold" rating in a report on Monday, March 24th. Robert W. Baird boosted their price objective on Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a report on Monday, January 27th. Finally, Leerink Partners initiated coverage on Medpace in a report on Monday, March 24th. They set a "market perform" rating and a $330.00 target price on the stock.

Medpace Price Performance

MEDP traded down $7.67 on Friday, reaching $304.69. The company's stock had a trading volume of 602,622 shares, compared to its average volume of 299,947. Medpace has a 1 year low of $289.21 and a 1 year high of $459.77. The business's 50 day moving average is $335.25 and its 200 day moving average is $338.90. The stock has a market cap of $9.28 billion, a price-to-earnings ratio of 24.12, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47.

Remove Ads

Medpace (NASDAQ:MEDP - Get Free Report) last released its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, research analysts forecast that Medpace will post 12.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Medpace

Institutional investors have recently modified their holdings of the company. R Squared Ltd acquired a new position in Medpace during the 4th quarter valued at about $30,000. SBI Securities Co. Ltd. bought a new stake in shares of Medpace during the fourth quarter valued at approximately $31,000. Jones Financial Companies Lllp boosted its position in shares of Medpace by 2,750.0% during the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock worth $38,000 after buying an additional 110 shares during the period. Lindbrook Capital LLC grew its holdings in Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock worth $45,000 after buying an additional 29 shares in the last quarter. Finally, True Wealth Design LLC increased its position in Medpace by 16,800.0% in the 3rd quarter. True Wealth Design LLC now owns 169 shares of the company's stock valued at $56,000 after acquiring an additional 168 shares during the period. Institutional investors own 77.98% of the company's stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.